Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers.
However, treatment with cisplatin is associated with drug resistance and several adverse …

Malignantly transformed cells must alter their metabolic status to stay viable in a harsh
microenvironment and maintain their ability to invade and spread. Anoikis, a specific …

Fatty acid synthase (FASN) and ATP-citrate lyase, key enzymes of de novo lipogenesis, are
significantly upregulated and activated in many cancers and portend poor prognosis. Even …

Abstract Salt-inducible kinase 2 (SIK2) has been established as a regulator of diverse
biological processes including cell metabolism. A recent study has reported that SIK2 is …

Overexpression of fatty acid synthase (FASN), a key regulator of the de novo synthesis of
fatty acids, has been demonstrated in a variety of cancers and is associated with poor …

Background Fatty acid synthase (FASN) is crucial to de novo long-chain fatty acid synthesis,
needed to meet cancer cells' increased demands for membrane, energy, and protein …

Cisplatin is one of the most potent and widely used chemotherapeutic agent in the treatment
of several solid tumors, despite the high toxicity and the frequent relapse of patients due to …

Fatty acid synthase (FASN), responsible for the de novo synthesis of fatty acids, has been
shown to act as an oncogene in various human cancers. However, the mechanisms by …

Ovarian cancer (OC) is caused by genetic aberrations in networks that control growth and
survival. Importantly, aberrant cancer metabolism interacts with oncogenic signaling …

Purpose Lung cancer is one of the most common causes of death from cancer. Serum
markers that enable diagnosis of the disease in the early stage have not been found …